Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Single-center, open-label, pre-post treatment pilot study to evaluate the safety and
 effectiveness of sphenopalatine ganglia blocks for the treatment of chronic migraine in the
 pediatric population. 50 children with a diagnosis of chronic migraines will undergo a series
 of three transnasal sphenopalatine ganglia blocks to measure their effect on headache
 frequency, headache intensity, headache duration, and use of headache medication.
Inclusion Criteria:

 Children ages 8 to 17 years old Meet the criteria for chronic migraines Have remained
 stable on their current headache medication for a minimum of 4 weeks.

 Able to provide informed consent from parent or legal guardian Able to provide assent if
 subject is a minor of appropriate age

 Exclusion Criteria:

 Allergy to local anesthetic Developmental delay (e.g. non-verbal) Inability to use numeric
 pain scale Inability to perform or tolerate transnasal procedure Substance abuse disorders
 Known pregnancy